Blueprint Medicines Corporation announced a second expansion of its collaboration and license agreement with VantAI, a leader in generative AI and proximity-based therapeutics. This expanded partnership incorporates additional drug target programs, building on the successful collaboration initiated in 2022.
Under the terms of the expanded agreement, VantAI is eligible to receive up to $1.67 billion in potential research, development, regulatory, and sales milestone payments. This includes up to $1.4 billion in sales milestones and up to $270 million in research, development, and regulatory milestones, in addition to tiered royalties on future net sales of certain products.
The collaboration aims to advance induced proximity drug discovery by pursuing targets and mechanisms previously considered 'undruggable' through conventional methods, leveraging VantAI’s Neo-1 foundation model. Blueprint Medicines retains the option to further expand the collaboration to additional target programs, signaling a long-term commitment to this innovative approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.